Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Colorcon
QuintilesIMS
Covington
Mallinckrodt

Generated: March 26, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL; LEVONORGESTREL

« Back to Dashboard

Clinical Trials for Ethinyl Estradiol; Levonorgestrel

Trial ID Title Status Sponsor Phase Summary
NCT00117273 A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens Completed Duramed Research Phase 3 This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
NCT00128934 Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE) is effective in treating the symptoms of severe premenstrual syndrome (PMS).
NCT00161681 Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 The purpose of this study is to determine whether LNG/EE is effective in the treatment of menstrual cycle related symptoms.
NCT00195559 Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ethinyl Estradiol; Levonorgestrel

Condition Name

Condition Name for Ethinyl Estradiol; Levonorgestrel
Intervention Trials
Contraception 13
Healthy 11
Drug Interactions 3
Endometriosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ethinyl Estradiol; Levonorgestrel
Intervention Trials
Endometriosis 3
Premenstrual Syndrome 3
Premenstrual Dysphoric Disorder 2
Menstruation Disturbances 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ethinyl Estradiol; Levonorgestrel

Trials by Country

Trials by Country for Ethinyl Estradiol; Levonorgestrel
Location Trials
United States 125
China 12
Germany 10
Canada 6
Mexico 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ethinyl Estradiol; Levonorgestrel
Location Trials
Florida 12
California 8
Arizona 6
Texas 6
Washington 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ethinyl Estradiol; Levonorgestrel

Clinical Trial Phase

Clinical Trial Phase for Ethinyl Estradiol; Levonorgestrel
Clinical Trial Phase Trials
Phase 4 6
Phase 3 17
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ethinyl Estradiol; Levonorgestrel
Clinical Trial Phase Trials
Completed 34
Recruiting 5
Withdrawn 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ethinyl Estradiol; Levonorgestrel

Sponsor Name

Sponsor Name for Ethinyl Estradiol; Levonorgestrel
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 8
Bayer 5
Agile Therapeutics 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ethinyl Estradiol; Levonorgestrel
Sponsor Trials
Industry 40
Other 16
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Argus Health
US Department of Justice
Chubb
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.